HI 6 human serum albumin nanoparticles-Development and transport over an in vitro blood-brain barrier model
HI 6 human serum albumin nanoparticles-Development and transport over an in vitro blood-brain barrier model
复制标题
DOI:
10.1016/j.toxlet.2011.06.027
复制
发表时间:
2011-09-25
影响因子:
3.5
通讯作者:
Kreuter, Joerg
中科院分区:
文献类型:
--
作者:
Dadparvar, Miriam;Wagner, Sylvia;Kreuter, Joerg
The standard treatment of intoxication with organophosphorus (OP) compounds includes the administration of oximes acting as acetylcholinesterase (AChE) reactivating antidotes. However, the blood-brain barrier (BBB) restricts the rapid transport of these drugs from the blood into the brain in therapeutically relevant concentrations. Since human serum albumin (HSA) nanoparticles enable the delivery of a variety of drugs across the BBB into the brain. HI 6 dimethanesulfonate and HI 6 dichloride monohydrate were bound to these nanoparticles in the present study. The resulting sorption isotherms showed a better fit to Freundlich's empirical adsorption isotherm than to Langmuir's adsorption isotherm. At the pH of 8.3 maximum drug binding capacities of 344.8 mu g and 322.6 mu g per mg of nanoparticles were calculated for HI 6 dimethanesulfonate and HI 6 dichloride monohydrate, respectively. These calculated values are higher than the adsorption capacity of 93.5 mu g/mg for obidoxime onto HSA nanoparticles determined in a previous study. In vitro testing of the nanoparticulate oxime formulations in primary porcine brain capillary endothelial cells (pBCEC) demonstrated an up to two times higher reactivation of OP-inhibited AChE than the free oximes. These findings show that nanoparticles made of HSA may enable a sufficient antidote OP-poisoning therapy with HI 6 derivatives even within the central nervous system (CNS). (C) 2011 Elsevier Ireland Ltd. All rights reserved.